Set up alerts on Stock Price, Dividend Yield, Valuation (e.g. P/E or EV/Sales) or Strategy Scores and sit back and relax.
24 Analysts have issued a Qiagen forecast:
24 Analysts have issued a Qiagen forecast:
| Sep '25 |
+/-
%
|
||
| Revenue | 1,789 1,789 |
5%
5%
|
|
| Gross Profit | 1,147 1,147 |
7%
7%
|
|
| EBITDA | 490 490 |
18%
18%
|
|
| EBIT (Operating Income) EBIT | 484 484 |
19%
19%
|
|
| Net Profit | 350 350 |
336%
336%
|
|
In millions EUR.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
QIAGEN NV is a holding company, which engages in the provision of sample and assay technology to transform biological samples into valuable molecular insights. It offers bioinformatics, molecular diagnostics, next-gen sequencing, and genomic services. The company was founded by Detlev H. Riesner and Metin Colpan on April 29, 1996 and is headquartered in Venlo, the Netherlands.
| Head office | United States |
| CEO | Thierry Bernard |
| Employees | 5,232 |
| Founded | 1996 |
| Website | www.qiagen.com |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.


